Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.

导出 OA

翻译打印收藏纠错

第一作者： Henry N,Ginsberg

第一单位： Columbia University College of Physicians and Surgeons, Irving Institute for Clinical and Translational Research, Columbia University, 622 West 168th Street, New York, NY, 10032, USA. hng1@cumc.columbia.edu.

作者： Henry N,Ginsberg ^[1] ; Daniel J,Rader ^[2] ; Frederick J,Raal ^[3] ; John R,Guyton ^[4] ; Marie T,Baccara-Dinet ^[5] ; Christelle,Lorenzato ^[6] ; Robert,Pordy ^[7] ; Erik,Stroes ^[8]

作者单位： Columbia University College of Physicians and Surgeons, Irving Institute for Clinical and Translational Research, Columbia University, 622 West 168th Street, New York, NY, 10032, USA. hng1@cumc.columbia.edu. ^[1] Departments of Medicine and Genetics, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA. ^[2] Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa. ^[3] Duke University Medical Center, Durham, NC, USA. ^[4] Sanofi, Montpellier, France. ^[5] Sanofi, Paris, France. ^[6] Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. ^[7] Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. ^[8]

关键词 Alirocumab Cardiovascular disease prevention Cholesterol-lowering drugs Familial hypercholesterolemia LDL-C PCSK9